This month, the editors of the AACR’s journals have chosen to highlight an analysis of birth characteristics and risk of early-onset synovial sarcoma, early research aimed at reducing intestinal toxicity brought on by radiotherapy, and a multicenter study evaluating how patients with cancer fare when hospitalized with COVID-19, among other interesting studies. As always, the articles highlighted here are freely available for a limited time.
Persistent infections with pathogens—such as the human papillomavirus (HPV), hepatitis B and C viruses (HBV/HCV), H. pylori, and others—represent a major risk factor for cancer incidence worldwide. Indeed, an analysis published in Lancet Oncology estimated that 2.2 million cancer cases in 2018 were attributable to infections, representing 13 percent of all global cancer cases (excluding non-melanoma skin cancers). While vaccines exist for many of these pathogens, access to them is not universal.
The FDA approved the use of an immune checkpoint inhibitor as a first-line treatment for patients with colorectal cancers caused by genetic mutations that stem from an inability to repair mistakes or damage in DNA coding.
A study finds that hereditary mutations are elevated in early-onset cancers, and more news of the week from Cancer Today.
Some cancers that are most commonly diagnosed in older adults are becoming increasingly prevalent in young adults.
Researchers are investigating why certain patients have an exceptional response to a particular drug.
COVID-19 has had a disproportionate impact on Black and Latino Americans, as well as members of other minority groups.
Communication gaps can shift extra burden to parents.
The AACR NextGen Grants for Transformative Cancer Research support early-career investigators who are pursuing highly innovative cancer research projects that have the potential to transform the field’s understanding of cancer development and/or treatment.
The FDA approved the use of an immune checkpoint inhibitor to treat certain patients with cutaneous squamous cell carcinoma.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More